Table 5.
Hazard ratios for progression and death (respectively) within the trial period, by frailty category (for each frailty measure).
| Survival outcomes Hazard ratios (HR) for progression and death respectively, calculated via cox proportional hazards regression |
|||||
|---|---|---|---|---|---|
| Score | Unadjusted HR for progression (CI) | Adjusteda HR for progression (CI) | Unadjusted HR for death (CI) | Adjusteda HR for death (CI) | |
| PS category | 0 | 1 | 1 | 1 | 1 |
| 1 | 1.01 (0.76, 1.33) | 0.99 (0.75, 1.31) | 0.92 (0.68, 1.25) | 0.93 (0.68, 1.25) | |
| 2 | 1.44 (1.06, 1.95) | 1.31 (0.96, 1.78) | 1.46 (1.06, 2.01) | 1.33 (0.96, 1.85) | |
| >2 | 1.36 (0.74, 2.53) | 1.27 (0.68, 2.40) | 1.03 (0.51, 2.08) | 0.96 (0.47, 2.00) | |
| GO2FS category | Not frail (0–1) | 1 | 1 | 1 | 1 |
| Frail (2) | 1.11 (0.83, 1.50) | 1.07 (0.79, 1.44) | 1.09 (0.78, 1.51 | 1.09 (0.78, 1.52) | |
| Sev frail (≥3) | 1.47 (1.14, 1.90) | 1.44 (1.11, 1.85)b | 1.62 (1.23, 2.14) | 1.66 (1.25, 2.20)b | |
| mCFS category | Fit (1–2) | 1 | 1 | 1 | 1 |
| Pre-frail (3–4) | 1.54 (1.19, 2.00) | 1.57 (1.21, 2.05)b | 1.65 (1.25, 2.19) | 1.71 (1.29, 2.28)b | |
| Frail (5+) | 1.66 (1.34, 2.06) | 1.63 (1.30, 2.03)b | 1.72 (1.35, 2.18) | 1.75 (1.37, 2.22)b | |
| G8 category | ≤14 (‘abnormal’) | 1 | 1 | 1 | 1 |
| >14 (‘normal’) | 0.63 (0.44, 0.90) | 0.63 (0.44, 0.90)b | 0.54 (0.35, 0.81) | 0.54 (0.36, 0.82)b | |
| CARG toxicity risk category | Low (0–5) | 1 | 1 | 1 | 1 |
| Med (6–9) | 0.88 (0.61, 1.25) | 1.13 (0.77, 1.66) | 0.88 (0.60, 1.28) | 1.17 (0.78, 1.77) | |
| High (10–19) | 0.92 (0.64, 1.32) | 1.25 (0.83, 1.86) | 0.90 (0.62, 1.33) | 1.26 (0.83, 1.92) | |
Statistically significant results in bold. a = adjusted for: age group, sex, histology, presence of metastases, planned use of trastuzumab, dose reduction due to renal/hepatic impairment. b = significant after adding in PS to adjustment factors.
Abbreviations: OTU = overall treatment utility, PS = Performance Status, GO2FS = GO2 Frailty Score, mCFS = ‘modified’ Clinical Frailty Scale, G8 = Geriatric-8, CARG = Cancer and Aging Research Group.